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Hoesein et al.,1 in a comprehensive and balanced review of
the literature, addressed the question whether the diag-
nosis of airways obstruction should be based on an FEV1/FVC
ratio < 0.70 (fixed ratio), or below the lower limit of normal
(LLN, commonly the 5th centile). A clinical diagnosis is
commonly confirmed by combining clinical information with
test results, presented with their lower and upper limits of
normal. The GOLD committee deviated from the time-
honoured and scientifically based practise by replacing the
LLN with a fixed FEV1/FVC ratio,
2 with no evidence that this
was a valid way of diagnosing airways obstruction, aka
chronic obstructive lung disease (COPD). Many studies have
since unsuccessfully tried to find evidence that there may
be any merit in using the fixed ratio for diagnosing COPD.
Hoesein et al.’s1 final conclusion hinges on one publica-
tion3; it allegedly showed that subjects with an FEV1/FVC
ratio < 0.70 but > LLN had an increased risk of premature
death and hospitalisation for COPD. However, the adjusted
hazard ratio for death was misquoted: it was not elevated
(1.1, confidence interval 0.96e1.3, see table 3 in3). An
increased hazards ratio for hospitalisation was reported, but
the authors conceded that ‘the measure of COPD-related
hospitalisations was too inclusive’,4 so this finding also fails
under scrutiny. Regardless, it is circular reasoning to postu-
late that an FEV1/FVC ratio < 0.70 represents COPD, and
subsequently consider any death or hospitalisation in
subjects with such a ratio as confirming the diagnosis of
COPD. Subjects with FEV1/FVC < LLN, but not non-smokers
with FEV1/FVC < 0.70 but > LLN, have an increased risk of
all-cause death.5,6 GOLD stage I in asymptomatic subjects is
not associated with dyspnoea, accelerated decline in FEV1,
respiratory care utilisation or quality of life scores compared
with a reference group.7 It is therefore safe to assume that
GOLD COPD stage I in the above studies3,5,6 represented
healthy subjects with FEV1/FVC > LLN.
All the evidence, including that from all longitudinal
studies, is therefore that GOLD COPD stage I does not
represent disease. Therefore the ‘twilight zone’ (FEV1/
FVC < 0.70 but > LLN) deserves no attention. Apart from
smoking cessation, for which all smokers should get all the
help available regardless of pulmonary function, there is no
intervention that will favourably affect their lung condi-
tion. As the authors and Bridevaux et al.7 suggest, in0954-6111/$ - see front matter ª 2011 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2011.07.025establishing a diagnosis one should put more emphasis on
prior probability of disease, clinical signs and symptoms.
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